<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34894966</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways.</ArticleTitle>
        <Pagination>
          <StartPage>118</StartPage>
          <EndPage>124</EndPage>
          <MedlinePgn>118-124</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2021.1995379</ELocationID>
        <Abstract>
          <AbstractText>Hepatic stellate cells activation (HSCs) plays a crucial role in the pathogenesis of liver fibrosis. Specific microRNAs have been suggested to affect the activation of HSCs via various signalling pathways including TGF-β/smads and Wnt/β-catenin pathways. Dasatinib is a multitarget inhibitor of many tyrosine kinases has recently studied for its anti-fibrotic effects in a variety of fibrous diseases. This study investigated the role of modulation of miRNA-378 and miRNA-17 in the pathogenesis of liver fibrosis through altering Wnt/β-catenin and TGF-β/smads pathways and evaluated the beneficial effect of the tyrosine kinase inhibitor, dasatinib, in thioacetamide-induced liver fibrosis model in mice. Treatment with dasatinib down-regulated miRNA-17 expression, leading to the restoration of WiF-1 and smad-7 which cause the inhibition of both Wnt/β-catenin and TGF-β/smads signalling. In addition, it upregulated miRNA-378 leading to the decrease of Wnt-10 which contributes to the suppression of activated HSCs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zaafan</LastName>
            <ForeName>Mai A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0002-5295-0003</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Pharmacology and Toxicology Department, October University for Modern Sciences and Arts (MSA), Dokki, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdelhamid</LastName>
            <ForeName>Amr M</ForeName>
            <Initials>AM</Initials>
            <Identifier Source="ORCID">0000-0002-2324-6826</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Biochemistry Department, October University for Modern Sciences and Arts (MSA), Dokki, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C546119">MIRN378 microRNA, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C543614">Mirn17 microRNA, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497806">SMAD7 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051906">Smad7 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>075T165X8M</RegistryNumber>
          <NameOfSubstance UI="D013853">Thioacetamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RBZ1571X5H</RegistryNumber>
          <NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051906" MajorTopicYN="N">Smad7 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013853" MajorTopicYN="N">Thioacetamide</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dasatinib</Keyword>
        <Keyword MajorTopicYN="N">Wnt-10</Keyword>
        <Keyword MajorTopicYN="N">liver fibrosis</Keyword>
        <Keyword MajorTopicYN="N">mice</Keyword>
        <Keyword MajorTopicYN="N">smad-3</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>11</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34894966</ArticleId>
        <ArticleId IdType="pmc">PMC8667920</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2021.1995379</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Marcellin P, Kutala BK.. 
Liver diseases: a major, neglected global public health problem requiring urgent actions and large‐scale screening. Liver Int
2018;38:2–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29427496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang YH, Chen MH, Guo QL, et al. . 
Interleukin-10 induces senescence of activated hepatic stellate cells via STAT3-p53 pathway to attenuate liver fibrosis. Cell Signal
2020;66:109445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31730896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duval F, Moreno-Cuevas JE, González-Garza MT, et al. . 
Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis. Chinese Med
2014;9:27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4299307</ArticleId>
            <ArticleId IdType="pubmed">25606051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomaa A, Allam N, Elsharkawy A, et al. . 
Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med
2017;9:17–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5439968</ArticleId>
            <ArticleId IdType="pubmed">28553150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang PM-K, Zhang Y-Y, Lan H-Y.. 
LncRNAs in TGF-β-driven tissue fibrosis. Non-Coding RNA
2018;4:26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6315857</ArticleId>
            <ArticleId IdType="pubmed">30287731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishikawa K, Osawa Y, Kimura K.. 
Wnt/β-catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs. Int J Mol Sci
2018;19:3103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6213128</ArticleId>
            <ArticleId IdType="pubmed">30308992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baarsma H, Königshoff M.. 
‘WNT-er is coming’: WNT signalling in chronic lung diseases. Thorax
2017;72:746–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5537530</ArticleId>
            <ArticleId IdType="pubmed">28416592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruglikov IL.
Interfacial adipose tissue in systemic sclerosis. Curr Rheumatol Rep
2017;19:4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5283508</ArticleId>
            <ArticleId IdType="pubmed">28138823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng X, Zhang Y, Xu H, et al. . 
Secreted frizzled related protein 2 modulates epithelial-mesenchymal transition and stemness via Wnt/β-catenin signaling in choriocarcinoma. Cell Physiol Biochem
2018;50:1815–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30396168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaafan MA, Abdelhamid AM.. 
The cardioprotective effect of microRNA-103 inhibitor against isoprenaline-induced myocardial infarction in mice through targeting FADD/RIPK pathway. Eur Rev Med Pharmacol Sci
2021;25:837–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33577038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaker OG, Ayeldeen G, Abdelhamid AM.. 
Circulating microRNA-944 and its target gene EPHA7 as a potential biomarker for colorectal cancer. Arch Physiol Biochem
2020:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32421395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambrecht J, Mannaerts I, van Grunsven LA.. 
The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis. Front Physiol
2015;6:209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4516870</ArticleId>
            <ArticleId IdType="pubmed">26283969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dituri F, Cossu C, Mancarella S, Giannelli G.. 
The interactivity between tgfβ and bmp signaling in organogenesis, fibrosis, and cancer. Cells
2019;8:1130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6829314</ArticleId>
            <ArticleId IdType="pubmed">31547567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Guo Y, Chen B, et al. . 
MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab Invest
2015;95:781–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25915722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Lu Z, Huang K, et al. . 
MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis. Oncotarget
2016;7:81–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4807984</ArticleId>
            <ArticleId IdType="pubmed">26637809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganguly N, Chakrabarti S.. 
Role of long non‑coding RNAs and related epigenetic mechanisms in liver fibrosis. Int J Mol Med
2021;47:1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7846421</ArticleId>
            <ArticleId IdType="pubmed">33495817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N.. 
Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis. Oncotarget
2017;8:90579–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685775</ArticleId>
            <ArticleId IdType="pubmed">29163854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Fan X, Chen B, et al. . 
Activation of hepatic stellate cells is inhibited by microRNA-378a-3p via Wnt10a. Cell Physiol Biochem
2016;39:2409–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado IF, Teodoro JS, Palmeira CM, Rolo AP.. 
miR-378a: a new emerging microRNA in metabolism. Cell Mol Life Sci
2020;77:1947–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31748917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araujo JC, Mathew P, Armstrong AJ, et al. . 
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer
2012;118:63–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3898168</ArticleId>
            <ArticleId IdType="pubmed">21976132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCafferty EH, Dhillon S, Deeks ED.. 
Dasatinib: a review in pediatric chronic myeloid leukemia. Paediatr Drugs
2018;20:593–600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30465234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng X-P, Wang L-J, Guo H-L, et al. . 
Dasatinib ameliorates chronic pancreatitis induced by caerulein via anti-fibrotic and anti-inflammatory mechanism. Pharmacol Res
2019;147:104357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31356863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi S, Jung HJ, Kim MW, et al. . 
A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice. Biochem Biophys Res Commun
2019;513:49–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30935693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang HY, Kim KS, Lee YH, et al. . 
Dendropanax morbifera ameliorates thioacetamide-induced hepatic fibrosis via TGF-β1/Smads pathways. Int J Biol Sci
2019;15:800–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6429015</ArticleId>
            <ArticleId IdType="pubmed">30906211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bancroft JD, Gamble M.. 
Theory and practice of histological techniques. Amsterdam, The Netherlands: Elsevier Health Sciences; 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaafan MA, Haridy AR, Abdelhamid AM.. 
Amitriptyline attenuates bleomycin-induced pulmonary fibrosis: modulation of the expression of NF-κβ, iNOS, and Nrf2. Naunyn-Schmiedeberg’s Arch Pharmacol
2019;392:279–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30474696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoline M.
The status of multiple comparisons: simultaneous estimation of all pairwise comparisons in one-way ANOVA designs. J Am Stat Assoc.
1981;35:134–41.</Citation>
        </Reference>
        <Reference>
          <Citation>Samarakoon R, Overstreet JM, Higgins PJ.. 
TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal
2013;25:264–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3508263</ArticleId>
            <ArticleId IdType="pubmed">23063463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao H, Wang C, Chen X, et al. . 
Inhibition of Wnt/β-catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis. Scientific Rep
2018;8:13644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6134002</ArticleId>
            <ArticleId IdType="pubmed">30206265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao W, Jiang W, Shen J, et al. . 
Retinoic acid ameliorates pancreatic fibrosis and inhibits the activation of pancreatic stellate cells in mice with experimental chronic pancreatitis via suppressing the Wnt/β-catenin signaling pathway. PLoS One
2015;10:e0141462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4640570</ArticleId>
            <ArticleId IdType="pubmed">26556479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krejci P, Aklian A, Kaucka M, et al. . 
Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS One
2012;7:e35826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3338780</ArticleId>
            <ArticleId IdType="pubmed">22558232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martyanov V, Kim G-HJ, Hayes W, et al. . 
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS One
2017;12:e0187580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5679625</ArticleId>
            <ArticleId IdType="pubmed">29121645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdalla M, Thompson L, Gurley E, et al. . 
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway. Eur J Pharmacol
2015;769:134–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4679708</ArticleId>
            <ArticleId IdType="pubmed">26548624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Huang C, Zhang S-P, et al. . 
The potential of microRNAs in liver fibrosis. Cell Signal
2012;24:2268–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22884954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaker O, Ayeldeen G, Abdelhamid A.. 
The impact of single nucleotide polymorphism in the long non-coding MEG3 gene on microRNA-182 and microRNA-29 expression levels in the development of breast cancer in Egyptian women. Front Genet
2021;12:683809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8371747</ArticleId>
            <ArticleId IdType="pubmed">34421993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KK, Wei Y, Szekeres C, et al. . 
Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest
2009;119:213–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2613463</ArticleId>
            <ArticleId IdType="pubmed">19104148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kordes C, Sawitza I, Häussinger D.. 
Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun
2008;367:116–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18158920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng JH, She H, Han YP, et al. . 
Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol
2008;294:G39–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18006602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng H, Wan LY, Liang JJ, et al. . 
The roles of lncRNA in hepatic fibrosis. Cell and Biosci
2018;8:1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu HH, Chen DQ, Wang YN, et al. . 
New insights into TGF-β/Smad signaling in tissue fibrosis. Chemico-Biol Inter
2018;292:76–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30017632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X-m, Nikolic-Paterson DJ, Lan HY.. 
TGF-β: the master regulator of fibrosis. Nature Rev Nephrol
2016;12:325–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27108839</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34894966</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways.</ArticleTitle>
        <Pagination>
          <StartPage>118</StartPage>
          <EndPage>124</EndPage>
          <MedlinePgn>118-124</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2021.1995379</ELocationID>
        <Abstract>
          <AbstractText>Hepatic stellate cells activation (HSCs) plays a crucial role in the pathogenesis of liver fibrosis. Specific microRNAs have been suggested to affect the activation of HSCs via various signalling pathways including TGF-β/smads and Wnt/β-catenin pathways. Dasatinib is a multitarget inhibitor of many tyrosine kinases has recently studied for its anti-fibrotic effects in a variety of fibrous diseases. This study investigated the role of modulation of miRNA-378 and miRNA-17 in the pathogenesis of liver fibrosis through altering Wnt/β-catenin and TGF-β/smads pathways and evaluated the beneficial effect of the tyrosine kinase inhibitor, dasatinib, in thioacetamide-induced liver fibrosis model in mice. Treatment with dasatinib down-regulated miRNA-17 expression, leading to the restoration of WiF-1 and smad-7 which cause the inhibition of both Wnt/β-catenin and TGF-β/smads signalling. In addition, it upregulated miRNA-378 leading to the decrease of Wnt-10 which contributes to the suppression of activated HSCs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zaafan</LastName>
            <ForeName>Mai A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0002-5295-0003</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Pharmacology and Toxicology Department, October University for Modern Sciences and Arts (MSA), Dokki, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdelhamid</LastName>
            <ForeName>Amr M</ForeName>
            <Initials>AM</Initials>
            <Identifier Source="ORCID">0000-0002-2324-6826</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Biochemistry Department, October University for Modern Sciences and Arts (MSA), Dokki, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C546119">MIRN378 microRNA, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C543614">Mirn17 microRNA, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497806">SMAD7 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051906">Smad7 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>075T165X8M</RegistryNumber>
          <NameOfSubstance UI="D013853">Thioacetamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RBZ1571X5H</RegistryNumber>
          <NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051906" MajorTopicYN="N">Smad7 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013853" MajorTopicYN="N">Thioacetamide</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dasatinib</Keyword>
        <Keyword MajorTopicYN="N">Wnt-10</Keyword>
        <Keyword MajorTopicYN="N">liver fibrosis</Keyword>
        <Keyword MajorTopicYN="N">mice</Keyword>
        <Keyword MajorTopicYN="N">smad-3</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>11</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34894966</ArticleId>
        <ArticleId IdType="pmc">PMC8667920</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2021.1995379</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Marcellin P, Kutala BK.. 
Liver diseases: a major, neglected global public health problem requiring urgent actions and large‐scale screening. Liver Int
2018;38:2–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29427496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang YH, Chen MH, Guo QL, et al. . 
Interleukin-10 induces senescence of activated hepatic stellate cells via STAT3-p53 pathway to attenuate liver fibrosis. Cell Signal
2020;66:109445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31730896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duval F, Moreno-Cuevas JE, González-Garza MT, et al. . 
Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis. Chinese Med
2014;9:27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4299307</ArticleId>
            <ArticleId IdType="pubmed">25606051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomaa A, Allam N, Elsharkawy A, et al. . 
Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med
2017;9:17–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5439968</ArticleId>
            <ArticleId IdType="pubmed">28553150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang PM-K, Zhang Y-Y, Lan H-Y.. 
LncRNAs in TGF-β-driven tissue fibrosis. Non-Coding RNA
2018;4:26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6315857</ArticleId>
            <ArticleId IdType="pubmed">30287731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishikawa K, Osawa Y, Kimura K.. 
Wnt/β-catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs. Int J Mol Sci
2018;19:3103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6213128</ArticleId>
            <ArticleId IdType="pubmed">30308992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baarsma H, Königshoff M.. 
‘WNT-er is coming’: WNT signalling in chronic lung diseases. Thorax
2017;72:746–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5537530</ArticleId>
            <ArticleId IdType="pubmed">28416592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruglikov IL.
Interfacial adipose tissue in systemic sclerosis. Curr Rheumatol Rep
2017;19:4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5283508</ArticleId>
            <ArticleId IdType="pubmed">28138823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng X, Zhang Y, Xu H, et al. . 
Secreted frizzled related protein 2 modulates epithelial-mesenchymal transition and stemness via Wnt/β-catenin signaling in choriocarcinoma. Cell Physiol Biochem
2018;50:1815–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30396168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaafan MA, Abdelhamid AM.. 
The cardioprotective effect of microRNA-103 inhibitor against isoprenaline-induced myocardial infarction in mice through targeting FADD/RIPK pathway. Eur Rev Med Pharmacol Sci
2021;25:837–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33577038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaker OG, Ayeldeen G, Abdelhamid AM.. 
Circulating microRNA-944 and its target gene EPHA7 as a potential biomarker for colorectal cancer. Arch Physiol Biochem
2020:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32421395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambrecht J, Mannaerts I, van Grunsven LA.. 
The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis. Front Physiol
2015;6:209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4516870</ArticleId>
            <ArticleId IdType="pubmed">26283969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dituri F, Cossu C, Mancarella S, Giannelli G.. 
The interactivity between tgfβ and bmp signaling in organogenesis, fibrosis, and cancer. Cells
2019;8:1130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6829314</ArticleId>
            <ArticleId IdType="pubmed">31547567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Guo Y, Chen B, et al. . 
MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab Invest
2015;95:781–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25915722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Lu Z, Huang K, et al. . 
MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis. Oncotarget
2016;7:81–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4807984</ArticleId>
            <ArticleId IdType="pubmed">26637809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganguly N, Chakrabarti S.. 
Role of long non‑coding RNAs and related epigenetic mechanisms in liver fibrosis. Int J Mol Med
2021;47:1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7846421</ArticleId>
            <ArticleId IdType="pubmed">33495817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N.. 
Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis. Oncotarget
2017;8:90579–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685775</ArticleId>
            <ArticleId IdType="pubmed">29163854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Fan X, Chen B, et al. . 
Activation of hepatic stellate cells is inhibited by microRNA-378a-3p via Wnt10a. Cell Physiol Biochem
2016;39:2409–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado IF, Teodoro JS, Palmeira CM, Rolo AP.. 
miR-378a: a new emerging microRNA in metabolism. Cell Mol Life Sci
2020;77:1947–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31748917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araujo JC, Mathew P, Armstrong AJ, et al. . 
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer
2012;118:63–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3898168</ArticleId>
            <ArticleId IdType="pubmed">21976132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCafferty EH, Dhillon S, Deeks ED.. 
Dasatinib: a review in pediatric chronic myeloid leukemia. Paediatr Drugs
2018;20:593–600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30465234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng X-P, Wang L-J, Guo H-L, et al. . 
Dasatinib ameliorates chronic pancreatitis induced by caerulein via anti-fibrotic and anti-inflammatory mechanism. Pharmacol Res
2019;147:104357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31356863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi S, Jung HJ, Kim MW, et al. . 
A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice. Biochem Biophys Res Commun
2019;513:49–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30935693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang HY, Kim KS, Lee YH, et al. . 
Dendropanax morbifera ameliorates thioacetamide-induced hepatic fibrosis via TGF-β1/Smads pathways. Int J Biol Sci
2019;15:800–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6429015</ArticleId>
            <ArticleId IdType="pubmed">30906211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bancroft JD, Gamble M.. 
Theory and practice of histological techniques. Amsterdam, The Netherlands: Elsevier Health Sciences; 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaafan MA, Haridy AR, Abdelhamid AM.. 
Amitriptyline attenuates bleomycin-induced pulmonary fibrosis: modulation of the expression of NF-κβ, iNOS, and Nrf2. Naunyn-Schmiedeberg’s Arch Pharmacol
2019;392:279–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30474696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoline M.
The status of multiple comparisons: simultaneous estimation of all pairwise comparisons in one-way ANOVA designs. J Am Stat Assoc.
1981;35:134–41.</Citation>
        </Reference>
        <Reference>
          <Citation>Samarakoon R, Overstreet JM, Higgins PJ.. 
TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal
2013;25:264–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3508263</ArticleId>
            <ArticleId IdType="pubmed">23063463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao H, Wang C, Chen X, et al. . 
Inhibition of Wnt/β-catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis. Scientific Rep
2018;8:13644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6134002</ArticleId>
            <ArticleId IdType="pubmed">30206265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao W, Jiang W, Shen J, et al. . 
Retinoic acid ameliorates pancreatic fibrosis and inhibits the activation of pancreatic stellate cells in mice with experimental chronic pancreatitis via suppressing the Wnt/β-catenin signaling pathway. PLoS One
2015;10:e0141462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4640570</ArticleId>
            <ArticleId IdType="pubmed">26556479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krejci P, Aklian A, Kaucka M, et al. . 
Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS One
2012;7:e35826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3338780</ArticleId>
            <ArticleId IdType="pubmed">22558232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martyanov V, Kim G-HJ, Hayes W, et al. . 
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS One
2017;12:e0187580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5679625</ArticleId>
            <ArticleId IdType="pubmed">29121645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdalla M, Thompson L, Gurley E, et al. . 
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway. Eur J Pharmacol
2015;769:134–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4679708</ArticleId>
            <ArticleId IdType="pubmed">26548624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Huang C, Zhang S-P, et al. . 
The potential of microRNAs in liver fibrosis. Cell Signal
2012;24:2268–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22884954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaker O, Ayeldeen G, Abdelhamid A.. 
The impact of single nucleotide polymorphism in the long non-coding MEG3 gene on microRNA-182 and microRNA-29 expression levels in the development of breast cancer in Egyptian women. Front Genet
2021;12:683809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8371747</ArticleId>
            <ArticleId IdType="pubmed">34421993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KK, Wei Y, Szekeres C, et al. . 
Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest
2009;119:213–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2613463</ArticleId>
            <ArticleId IdType="pubmed">19104148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kordes C, Sawitza I, Häussinger D.. 
Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun
2008;367:116–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18158920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng JH, She H, Han YP, et al. . 
Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol
2008;294:G39–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18006602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng H, Wan LY, Liang JJ, et al. . 
The roles of lncRNA in hepatic fibrosis. Cell and Biosci
2018;8:1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu HH, Chen DQ, Wang YN, et al. . 
New insights into TGF-β/Smad signaling in tissue fibrosis. Chemico-Biol Inter
2018;292:76–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30017632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X-m, Nikolic-Paterson DJ, Lan HY.. 
TGF-β: the master regulator of fibrosis. Nature Rev Nephrol
2016;12:325–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27108839</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
